Evidence map›Paper›PMID 41444831›Full record

ArticleSurgical endoscopy2026

Robotic versus open cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a propensity score-matched study.

Ekaterina Baron, Zhesheng Xu, Alessandro Paro, Andrei Nikiforchin, Riya Singh, Jessica A Wernberg, Rohit Sharma

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ekaterina BaronSurgical Oncology, Marshfield Medical Center, 1000 North Oak Avenue, Marshfield, WI, 54449, USA. baron.ekaterina@marshfieldclinic.org.ORCID 0000-0001-9704-6547
Zhesheng XuNeuroscience Department, Pomona College, 333 North College Way, Claremont, CA, 91711, USA.
Alessandro ParoSurgical Oncology, Marshfield Medical Center, 1000 North Oak Avenue, Marshfield, WI, 54449, USA.ORCID 0000-0003-0620-4461
Andrei NikiforchinSurgical Oncology, Marshfield Medical Center, 1000 North Oak Avenue, Marshfield, WI, 54449, USA.ORCID 0000-0002-4772-5477
Riya SinghUniversity of California, Berkeley, 1 Centennial Drive, Berkeley, CA, 94720, USA.
Jessica A WernbergSurgical Oncology, Marshfield Medical Center, 1000 North Oak Avenue, Marshfield, WI, 54449, USA.
Rohit SharmaSurgical Oncology, Marshfield Medical Center, 1000 North Oak Avenue, Marshfield, WI, 54449, USA.ORCID 0000-0002-2884-3099

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is often associated with extensive surgical resection and has traditionally been performed via laparotomy. Data on minimally invasive robotic approaches remain limited. We evaluated surgical safety and survival outcomes of robotic CRS/HIPEC for peritoneal surface malignancies (PSM).

methodsA single-center propensity score-matched study was conducted using a prospectively collected database (2018-2025). PSM patients treated with robotic CRS/HIPEC were matched 1:1 to open CRS/HIPEC controls using propensity scores based on age, sex, BMI, histology, and PCI.

resultsOf 99 cases, 15 robotic and 71 open CRS/HIPECs were identified. After matching, 15 robotic and 15 open cases were balanced by age, sex, BMI, diagnosis, prior surgical score, and PCI. CC-0/1 rate was 100.0% in robotic and 93.3% in open CRS/HIPEC (p = 1.00). Median blood loss was lower in the robotic group (100 mL vs 250 mL, p = 0.04). Median hospital stay was shorter after robotic CRS/HIPEC (6 vs 9 days, p = 0.05). No differences were observed in major complications (26.7% vs 33.3%, p = 1.00) and reoperation (0.0% vs 6.7%, p = 1.00). No 90-day mortality was observed in either group. Median follow-up was 58 months. Median overall survival (not reached vs 52 months, p = 0.20) and progression-free survival (not reached vs 42 months, p = 0.19) did not differ between robotic and open CRS/HIPEC.

conclusionIn PSM patients with low tumor burden, robotic CRS/HIPEC is not associated with increased morbidity or worse survival. It may offer benefits such as reduced blood loss and shorter hospitalization. Multicenter studies are warranted to optimize patient selection.

Indexed as

Cytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyPeritoneal NeoplasmsRobotic Surgical ProceduresAdultAgedFemaleHumansLength of StayMaleMiddle AgedPropensity ScoreRetrospective StudiesAppendix cancerComplicationCRS/HIPECMinimally invasive surgeryRobotSurvival

Identifiers

PMID41444831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.